Confluent reticulated papillomatosis ose dermatosis ichthyosiform e le masani ai ae fa'apitoa e fa'aalia i le pogisa faifai pea, pa'u, pa'epa'e e masani ona maua i luga o le ogalaau tutotonu. Ole fa'ama'i e mafai ona togafitia ile Minocycline.
Confluent and reticulated papillomatosis of Gougerot and Carteaud is an uncommon but distinctive acquired ichthyosiform dermatosis characterized by persistent dark, scaly, papules and plaques that tend to be localized predominantly on the central trunk.
☆ I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
Tulaga masani ― E foliga mai o se mea lanu uliuli e leai ni fa'ailoga (feu, tiga) i le puimanava.
Confluent and reticulated papillomatosis (CRP) , e ta'ua fo'i le ma'i o le Gougerot-Carteaud, e mafua mai i le tuputupu a'e o le pa'u e le masani ai. E aliali mai o ni mea pogisa e le tiga e mafai ona tuʻufaʻatasia i ni paʻu tetele, e masani ona aliali i luga o le fatafata ma le ua o talavou ma talavou matutua. Ole filifiliga muamua ole togafitiga ole minocycline. Confluent and reticulated papillomatosis (CRP), also known as Gougerot-Carteaud syndrome, is caused by disordered keratinization. It presents with asymptomatic hyperpigmented papules that can coalesce into plaques and are typically located on the upper trunk and neck of teens and young adults. First-line treatment is oral 'minocycline'.
O le CRP e masani lava ona aliali mai o ni mea pogisa ma paʻu e aunoa ma ni faʻailoga i luga o le paʻu i luga o le ua, lima, fatafata pito i luga, ma tua i luga. O nisi taimi, e mafai ona sosolo i luga i le muaulu ma lalo i le vaega o le pubic. O vaila'au fa'ama'i e pei o le minocycline ua avea ma filifiliga sili mo togafitiga. CRP typically presents as asymptomatic hyperpigmented papules and plaques with peripheral reticulation over the nape, axillae, upper chest, and upper back, occasionally with extension superior to the forehead and inferior to the pubic region. Antibiotics, such as 'minocycline', at anti-inflammatory doses have emerged as a preferred therapeutic option.
○ Togafiti
#Minocycline